Drugs / Tabalumab
Tabalumab
English name tabalumab
also known as
LY2127399
Monoclonal antibody targets TNFSF13B via inhibition
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01556438 | Jul 2012 → Feb 2015 | plasma cell myeloma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01253291 | May 2010 → Sep 2013 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01253226 | Sep 2009 → Aug 2011 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00689507 | Mar 2008 → Jan 2013 | plasma cell myeloma | Applied Molecular Evolution | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT01602224 | Jul 2012 → Jul 2014 | plasma cell myeloma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01576549 | May 2012 → May 2013 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT01200290 | Apr 2011 → Mar 2014 | chronic renal failure syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00882999 | Apr 2009 → Feb 2011 | relapsing-remitting multiple sclerosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00837811 | Feb 2009 → Jan 2011 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00785928 | Oct 2008 → Jan 2010 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00689728 | Jun 2008 → Feb 2010 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00308282 | Mar 2006 → Jun 2007 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT02041091 | Jan → Oct 2014 | systemic lupus erythematosus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01676701 | Sep 2012 → Aug 2013 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01488708 | Jan 2012 → Oct 2015 | systemic lupus erythematosus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01215942 | Jun 2011 → Feb 2014 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01205438 | Jan 2011 → Aug 2014 | systemic lupus erythematosus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01202773 | Jan 2011 → Mar 2013 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01202760 | Jan 2011 → Dec 2012 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01196091 | Dec 2010 → Jul 2014 | systemic lupus erythematosus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01198002 | Dec 2010 → Dec 2012 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tabalumab | “To assess the dose-response relationship, efficacy and safety of tabalumab, a human monoclonal antibody that neutralises membrane-bound and soluble B-cell activating factor...” PMID 23599435 ↗ Apr 20138“Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate...” PMID 25873635 ↗ Apr 2015 “A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.” PMID 25168268 ↗ Aug 2014 “OBJECTIVE: Tabalumab, a fully human IgG4 monoclonal antibody, neutralizes soluble and membrane-bound BAFF.” PMID 23359344 ↗ Apr 2013 “LY2127399 (Tabalumab)” NCT01253226 ↗ |
| Known as | LY2127399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00689507 ↗ |
| Action | Inhibit | “neutralizes soluble and membrane-bound BAFF” PMID 23359344 ↗ Apr 2013 |
| Modality | Monoclonal antibody | “a fully human IgG4 monoclonal antibody” PMID 23359344 ↗ Apr 2013 |
| Route | Intravenous | “30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6” NCT00308282 ↗ |
| Target | TNFSF13B | “neutralizes soluble and membrane-bound BAFF” PMID 23359344 ↗ Apr 2013 |